*** STRICTLY EMBARGOED UNTIL 00:01 6TH AUGUST 2008***
Today’s decision by the Medicines and Healthcare products Regulatory Agency (MHRA) to approve the reclassification of azithromycin for the treatment of chlamydia infection will mean convenient and effective care for patients, said the Royal Pharmaceutical Society of Great Britain (RPSGB).
Azithromycin, currently licensed as a prescription-only medicine, is expected to be available for sale from pharmacies without a prescription later this year.
Pharmacists already play an important role in the provision of sexual health services, and have done so for many years. Reclassifying azithromycin will expand on existing services and improve access to chlamydia screening and treatment for patients.
